Skip to main content

Table 1 Utilisation of different Interferon Beta formulations

From: Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

 

Avonex®

Betaferon®

Extavia®

Plegridy®

Rebif®

Number

618

348

69

259

1220

Age, years

45.1 ± 13.8

48.1 ± 13.2

49.7 ± 14.2

42.1 ± 17.7

41.7 ± 16.0

Sex, females (%)

425 (68.77%)

211 (60.63%)

49 (71.01%)

178 (68.72%)

806 (66.06%)

Charlson comorbidity index

 0

301

172

43

107

632

 1–2

27

32

8

6

35

  > 2

3

3

1

3

7

  1. Table shows the number of individual treatment periods for different Interferon Beta formulations, along with age, sex distribution (with percentage), and Charlson comorbidity index (for patients with hospital records). The cohort included 2171 individuals, overall resulting into 2514 individual treatments with Interferon Beta